NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors, Appointment of Certain Officers; Compensatory
Arrangement of Certain Officers.
was resigning from her position as the Director of Finance of
Nemaura Medical, Inc. (the “Company”), effective immediately.
There were no disagreements between Ms. Farrar and the Company on
any matter relating to the Company’s operations, policies or
practices, that resulted in her resignation.
Anderson, to serve as the Chief Financial Officer.
Company on a part-time basis since August 2016. His
responsibilities include the preparation and management of the
Company’s accounts. Prior to his employment with the Company,
Mr. Anderson had more than 20 years’ experience in working for
US-owned businesses. From May 2014 to July 2016, Mr. Anderson was
the European Controller for Lamons (a division of TriMas
Corporation). From December 2013 to April 2014, he was the
Financial Controller for SPS Technologies Limited (a subsidiary
of Precision Castparts Corporation). From May 2013 to November
2013, he was Head of Accounting Northern Europe for Hospira, Inc.
From May 2011 to April 2013, he was Financial Controller for Air
Bearings Limited (a subsidiary of Hitachi).
1992. Mr. Anderson received a Masters in Business Administration
from Loughborough University in 1999.
80,000 (approximately USD100,000), which amount shall be prorated
for the 2016 fiscal year. Either party may terminate employment
by providing the other party with no less than three months’
prior notice.
the officers of director of the Company. Mr. Anderson has not
engaged in any related party transactions.
|
Exhibit No.
|
Description
|
|
10.1
|
Compensation Arrangement for Chief Financial Officer
|
About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)
Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Recent Trading Information
NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) closed its last trading session 00.00 at 1.50 with 1,900 shares trading hands.
